Now showing items 1-1 of 1

    • Tricoci, Pierluigi; Huang, Zhen; Held, Claes; Moliterno, David J.; Armstrong, Paul W.; Van De Werf, Frans; White, Harvey D.; Aylward, Philip E.; Wallentin, Lars; Chen, Edmond; Lokhnygina, Yuliya; Pei, Jinglan; Leonardi, Sergio; Rorick, Tyrus L.; Kilian, Ann M.; Jennings (Massachussetts Medical Society, 2012)
      BACKGROUND: Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation. METHODS: In this multinational, double-blind, randomized trial, we compared vorapaxar ...